[Federal Register Volume 85, Number 120 (Monday, June 22, 2020)]
[Notices]
[Pages 37464-37466]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13316]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Development and
Commercialization of Fenoterol and Certain Fenoterol Analogues for the
Treatment of Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Aging, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this Notice to Paz
Pharmaceuticals, LLC of the State of Delaware.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before July 7, 2020 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Richard T. Girards, Jr., Esq., MBA, Senior
Technology Transfer Manager, National Institutes of Health, NCI
Technology Transfer Center by email ([email protected]) or phone
(240-276-6825).
SUPPLEMENTARY INFORMATION:
Intellectual Property
E-205-2006: Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol
analogues and their use in treating congestive heart failure
1. United States Provisional Patent Application No. 60/837,161,
filed 10 August 2006 (HHS Reference No. E-205-2006-0-US-01);
2. United States Provisional Patent Application No. 60/927,825,
filed 03 May 2007 (HHS Reference No. E-205-2006-1-US-01);
3. United States Patent Application No. 12/376,945, filed 09
February 2009 (HHS Reference No. E-205-2006-2-US-13);
4. United States Patent No. 8,703,826, issued 22 April 2014 (HHS
Reference No. E-205-2006-2-US-15);
5. United States Patent No. 9,522,871, issued 20 December 2016
(HHS Reference No. E-205-2006-2-US-19);
6. United States Patent No. 9,908,841, issued 06 March 2018 (HHS
Reference No. E-205-2006-2-US-22);
[[Page 37465]]
7. United States Patent No. 10,308,591, issued 04 June 2019 (HHS
Reference No. E-205-2006-2-US-26);
8. United States Patent No. 10,562,843, issued 18 February 2020
(HHS Reference No. E-205-2006-2-US-27);
9. International Patent Application No. PCT/US2007/075731, filed
10 August 2007 (HHS Reference No. E-205-2006-2-PCT-01);
10. Australia Patent No. 2007286051, issued 26 April 2013 (HHS
Reference No. E-205-2006-2-AU-02);
11. Australia Patent No. 2013202127, issued 25 September 2014
(HHS Reference No. E-205-2006-2-AU-16);
12. Australia Patent Application No. 2014224073, filed 11
September 2014 (HHS Reference No. E-205-2006-2-AU-20);
13. Brazil Patent Application No. PI0716495-5, filed 18 June
2009 (HHS Reference No. E-205-2006-2-BR-03);
14. Canada Patent No. 2660707, issued 08 July 2014 (HHS
Reference No. E-205-2006-2-CA-04);
15. China Patent No. 200780036155.9, issued 29 January 2014 (HHS
Reference No. E-205-2006-2-CN-05);
16. China Patent Application No. 201310705914.3, filed 10 August
2007 (HHS Reference No. E-205-2006-2-CN-18);
17. European Patent No. 2064174, issued 26 October 2016 (HHS
Reference No. E-205-2006-2-EP-06) and all of its national
validations;
18. Hong Kong Patent Application No. 14107948.2, filed 04 August
2014 (HHS Reference No. E-205-2006-2-HK-21);
19. Israel Patent No. 196965, issued 30 January 2016 (HHS
Reference No. E-205-2006-2-IL-07);
20. India Patent No. 266343, issued 28 April 2015 (HHS Reference
No. E-205-2006-2-IN-08);
21. Japan Patent No. 5302194, issued 28 June 2013 (HHS Reference
No. E-205-2006-2-JP-09);
22. Japan Patent Application No. 2013-129406, filed 20 June 2013
(HHS Reference No. E-205-2006-2-JP-17);
23. Korea (South) Patent No. 10-1378067, issued 19 March 2014
(HHS Reference No. E-205-2006-2-KR-10);
24. Mexico Patent No. 331996, issued 30 July 2015 (HHS Reference
No. E-205-2006-2-MX-11);
25. Philippines Patent Application No. 1-2009-500267, filed 10
August 2007 (HHS Reference No. E-205-2006-2-PH-12);
26. South Africa Patent No. 2009/00938, issued 28 April 2010
(HHS Reference No. E-205-2006-2-ZA-14); and
27. any and all other U.S. and ex-U.S. patents and patent
applications claiming priority to any one of the foregoing, now or
in the future.
E-013-2010: Use of fenoterol and fenoterol analogues in the treatment
of glioblastomas and astrocytomas
1. United States Provisional Patent Application No. 61/312,642,
filed 10 March 2010 (HHS Reference No. E-013-2010-0-US-01);
2. United States Patent No. 9,492,405, issued 15 November 2016
(HHS Reference No. E-013-2010-0-US-08);
3. United States Patent No. 10,130,594, issued 20 November 2018
(HHS Reference No. E-013-2010-0-US-10);
4. United States Patent No. 10,617,654, issued 14 April 2020
(HHS Reference No. E-013-2010-0-US-15);
5. United States Patent Application No. 16/806,659, filed 02
March 2020 (HHS Reference No. E-013-2010-0-US-16);
6. International Patent Application No. PCT/US2011/027988, filed
10 March 2011 (HHS Reference No. E-013-2010-0-PCT-02);
7. Australia Patent No. 2011224241, issued 21 August 2014 (HHS
Reference No. E-013-2010-0-AU-03);
8. Australia Patent No. 2014210656, issued 30 June 2016 (HHS
Reference No. E-013-2010-0-AU-09);
9. Brazil Patent Application No. BR112012022552-9, filed 10
March 2011 (HHS Reference No. E-013-2010-0-BR-04);
10. Canada Patent No. 2791702, issued 29 May 2018 (HHS Reference
No. E-013-2010-0-CA-05);
11. European Patent No. 2544676, issued 19 September 2018 (HHS
Reference No. E-013-2010-0-EP-06) and all of its national
validations;
12. Japan Patent No. 5837890, issued 13 November 2015 (HHS
Reference No. E-013-2010-0-JP-07);
13. any and all other U.S. and ex-U.S. patents and patent
applications claiming priority to any one of the foregoing, now or
in the future.
E-139-2012: Methods of regulating cannabinoid receptor activity-related
disorders and diseases
1. United States Provisional Patent Application No. 61/651,961,
filed 25 May 2012 (HHS Reference No. E-139-2012-0-US-01);
2. United States Provisional Patent Application No. 61/789,629,
filed 15 March 2013 (HHS Reference No. E-139-2012-1-US-01);
3. United States Patent Application No. 14/403,516, filed 24
November 2014 (HHS Reference No. E-139-2012-2-US-06);
4. United States Patent No. 10,130,593, issued 20 November 2018
(HHS Reference No. E-139-2012-2-US-11);
5. United States Patent No. 10,485,771, issued 26 November 2019
(HHS Reference No. E-139-2012-2-US-13);
6. United States Patent Application No. 16/600,234, filed 11
October 2019 (HHS Reference No. E-139-2012-2-US-14);
7. International Patent Application No. PCT/US2013/042457, filed
23 May 2013 (HHS Reference No. E-139-2012-2-PCT-01);
8. Australia Patent No. 2013266235, issued 21 September 2017
(HHS Reference No. E-139-2012-2-AU-02);
9. Canada Patent Application No. 2874655, filed 23 May 2013 (HHS
Reference No. E-139-2012-2-CA-03);
10. European Patent No. 2854855, issued 27 April 2016 (HHS
Reference No. E-139-2012-2-EP-04) and all of its national
validations;
11. Japan Patent No. 6130495, issued 21 April 2017 (HHS
Reference No. E-139-2012-2-JP-05);
12. any and all other U.S. and ex-U.S. patents and patent
applications claiming priority to any one of the foregoing, now or
in the future.
The patent and patent application rights in these inventions have
been assigned and/or exclusively licensed to the government of the
United States of America.
The prospective exclusive license territory may be worldwide and
the fields of use may be limited to the following: The development,
manufacture, distribution, sale and use for the treatment of cancer of
one or more of fenoterol and its analogues, either in combination or
not in combination with one or more other therapeutic agents.
These technologies disclose, e.g., the use of fenoterol and its
analogues for regulating cannabinoid (CB) receptor activity-related
disorders and disease, such as dysregulated CB receptors, including
treating a disorder or disease. These diseases may include but are not
limited to glioblastoma, hepatocellular carcinoma, liver cancer, colon
cancer, and/or lung cancer, all of which may be associated with altered
cannabinoid receptor activity. In one example, the technologies include
administering to a subject having or at risk of developing a disorder
or disease regulated by CB receptor activity an effective amount of
fenoterol or one of its analogues to reduce one or more symptoms
associated with the disorder or disease regulated by CB receptor
activity.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
404. The prospective exclusive license will be royalty bearing, and the
prospective exclusive license may be granted unless within fifteen (15)
days from the date of this published Notice, the National Cancer
Institute receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
[[Page 37466]]
Dated: June 12, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2020-13316 Filed 6-19-20; 8:45 am]
BILLING CODE 4140-01-P